Literature DB >> 15277641

Radiosurgery for cerebral arteriovenous malformations in hereditary hemorrhagic telangiectasia.

M Maarouf1, M Runge, M Kocher, M Zähringer, H Treuer, V Sturm.   

Abstract

The authors evaluated the efficacy of radiosurgery (RS) for cerebral arteriovenous malformations in hereditary hemorrhagic telangiectasia (HHT AVMs). Two patients with seven HHT AVMs were treated by linear accelerator-RS. Complete obliteration was achieved 18 to 24 months post-treatment without side effects. Because HHT AVMs are small and multiple, RS is superior to microsurgery because it is noninvasive and all AVMs can be treated in one session regardless of their location.

Entities:  

Mesh:

Year:  2004        PMID: 15277641     DOI: 10.1212/01.wnl.0000130197.31844.16

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Stereotactic LINAC radiosurgery for the treatment of brainstem cavernomas.

Authors:  M Fuetsch; F El Majdoub; M Hoevels; R P Müller; V Sturm; M Maarouf
Journal:  Strahlenther Onkol       Date:  2012-04       Impact factor: 3.621

2.  Neurovascular radiosurgery.

Authors:  M Söderman; W Y Guo; B Karlsson; D M Pelz; E Ulfarsson; T Andersson
Journal:  Interv Neuroradiol       Date:  2006-12-13       Impact factor: 1.610

3.  Surgical Treatment vs Nonsurgical Treatment for Brain Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia: A Retrospective Multicenter Consortium Study.

Authors:  Ali Tayebi Meybodi; Helen Kim; Jeffrey Nelson; Steven W Hetts; Timo Krings; Karel G terBrugge; Marie E Faughnan; Michael T Lawton
Journal:  Neurosurgery       Date:  2018-01-01       Impact factor: 4.654

Review 4.  [Osler's disease].

Authors:  F Ahlhelm; J Lieb; G Schneider; U Müller; S Ulmer
Journal:  Radiologe       Date:  2013-12       Impact factor: 0.635

Review 5.  Imaging of hereditary hemorrhagic telangiectasia.

Authors:  Marie-France Carette; Cosmina Nedelcu; Marc Tassart; Jean-Didier Grange; Marie Wislez; Antoine Khalil
Journal:  Cardiovasc Intervent Radiol       Date:  2008-10-30       Impact factor: 2.740

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.